Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Capital Expenditures (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Capital Expenditures for 11 consecutive years, with $126000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 102.99% to $126000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, up 95.67% year-over-year, with the annual reading at $1.1 million for FY2025, 95.67% up from the prior year.
  • Capital Expenditures for Q4 2025 was $126000.0 at Intellia Therapeutics, up from $29000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $12.4 million in Q4 2023, with the low at -$6.6 million in Q3 2023.
  • Average Capital Expenditures over 5 years is $1.5 million, with a median of $1.1 million recorded in 2022.
  • The sharpest move saw Capital Expenditures tumbled 775.79% in 2021, then skyrocketed 33364.71% in 2022.
  • Over 5 years, Capital Expenditures stood at $34000.0 in 2021, then surged by 33364.71% to $11.4 million in 2022, then rose by 9.27% to $12.4 million in 2023, then crashed by 133.94% to -$4.2 million in 2024, then skyrocketed by 102.99% to $126000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $126000.0, $29000.0, and $239000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.